Pharmaceutical Product Development (PPD), a global CRO, was named Best CRO Provider at the World ADC Awards. This recognition acknowledges the excellence and dedication of PPD Laboratories professionals in supporting clients’ antibody-drug conjugate (ADC) research to develop new anticancer therapies.
ADCs are complex biotherapeutic molecules, combining monoclonal antibodies with an attached payload of highly potent cytotoxic drugs. They are designed to target and destroy cancer tumor cells with high specificity and efficiency, while minimally impacting healthy cells. To date, PPD Laboratories’ experience includes more than 100 different ADC molecules.
PPD Laboratories has supported numerous ADC development programs since 2009, ranging from early development projects to preclinical good laboratory practice (GLP) and human clinical trials.
“This award is evidence that PPD Laboratories’ employees are at the leading edge of ADC research and are driven to help clients succeed in combating cancer,” said Chris Fikry, M.D., executive vice president of PPD Laboratories for PPD. “In the past five years, the bioanalytical lab has completed more than 5,000 studies, providing vital pharmacokinetic, pharmacodynamic and immunogenicity data to support our clients’ efforts to develop new medicines to improve health.”
PPD Laboratories’ scientists have extensive experience in bioanalytical testing utilizing diverse measurement technologies, including immunochemistry, chromatography-mass spectrometry, cell-based assays, flow cytometry and molecular genomics. PPD’s expertise includes small molecules, biologics, vaccines and biomarkers across a wide variety of therapeutic areas. In oncology, our largest therapeutic area, PPD Laboratories helped develop all of 2016’s top 20 cancer therapies.